Novartis plots 'next frontier' of MS treatment — and it could spell a buyout for a small Swiss player

A couple of months after getting its self-administered multiple sclerosis drug Kesimpta cleared by EU regulators, Novartis has found what it believes is “the next frontier” of MS treatment at a University of Zurich spinout — and it’s already laying the groundwork for a buyout.